UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 25, 2024
SELECT MEDICAL HOLDINGS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware | 001-34465 | 20-1764048 | ||
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
4714 Gettysburg Road, P.O. Box 2034
Mechanicsburg, PA 17055
(Address of principal executive offices) (Zip Code)
(717) 972-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, par value $0.001 per share | SEM | New York Stock Exchange (NYSE) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether either registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if either registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Amendment to 2020 Equity Incentive Plan
The annual meeting of stockholders (the “Annual Meeting”) of the Company was held on April 25, 2024. At the Annual Meeting, the stockholders of Select Medical Holdings Corporation (the “Company”), upon recommendation of the Board of Directors of the Company (the “Board”) approved an amendment to the Company’s 2020 Equity Incentive Plan (the “Plan”) to increase the total share reserve under the Plan to 5,925,000 shares and add a minimum vesting period of one year for awards granted under the Plan, with exceptions for (i) awards granted for up to an aggregate of five percent of the maximum number of shares authorized for issuance under the Plan and (ii) acceleration of vesting of awards in the case of certain qualifying terminations of employment and in the event of certain corporate transactions at the Company’s Human Capital and Compensation Committee’s discretion.
The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the text of the Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. A more detailed summary of the amendment to the Plan can be found in the “Approval of an Amendment to the Company’s 2020 Equity Incentive Plan—Proposal #3” in the definitive proxy statement for the Company’s 2024 annual meeting of stockholders filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 15, 2024 (the “2024 Proxy Statement”), which description is incorporated by reference herein.
Item 5.03 | Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
At the Annual Meeting, the Company’s stockholders approved an amendment to the Amended and Restated Certificate of Incorporation (the “Charter”), providing limited exculpation to covered officers in order to align with new Delaware law provisions. The amendment of Charter exculpates the Company’s officers from monetary liability for certain fiduciary duty breaches, to the extent permitted by Section 102(b)(7) of the Delaware General Corporation Law.
A description of the amendment can be found in “Approval of Amendment to the Amended and Restated Certificate of Incorporation to Include New Delaware Law Provisions Regarding Officer Exculpation—Proposal #5”in the Proxy Statement. The amendment of Charter became effective upon the filing of a certificate of amendment with the Delaware Secretary of State on April 26, 2024.
Item 5.07 | Submission of Matters to a Vote of Security Holders. |
At the Annual Meeting, the Company’s stockholders approved seven proposals. The proposals below are described in the Company’s definitive proxy statement dated March 15, 2024. The results are as follows:
Proposal 1: The Election of Three Class III Directors to the Board of Directors
Name | Votes For | Votes Against | Abstentions | Broker Non-Votes | ||||
James S. Ely III | 102,880,768 | 18,037,258 | 28,732 | 2,545,553 | ||||
Rocco A. Ortenzio | 114,949,540 | 5,968,478 | 28,740 | 2,545,553 | ||||
Thomas A. Scully | 114,375,405 | 6,542,501 | 28,852 | 2,545,553 |
Proposal 2: Non-Binding Advisory Vote on the Compensation of the Company’s Named Executive Officers
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
106,777,980 | 14,125,946 | 42,832 | 2,545,553 |
Proposal 3: Approval of Amendment to the Company’s 2020 Equity Incentive Plan to Increase the Total Share Reserve and Add a Minimum Vesting Period
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
119,196,980 | 1,718,471 | 31,307 | 2,545,553 |
Proposal 4: Ratification of the Appointment of PricewaterhouseCoopers LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2024
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
122,477,547 | 987,844 | 26,920 | 0 |
Proposal 5: Approval of Amendment to the Company’s Amended and Restated Certificate of Incorporation To Permit the Exculpation of Officers of the Company
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
116,474,404 | 4,352,165 | 119,189 | 2,545,553 |
Proposal 6: Non-Binding Advisory Vote on Stockholder’s Simple Majority Proposal
Votes For | Votes Against | Abstentions | Broker Non-Votes | |||
74,680,241 | 46,242,865 | 23,652 | 2,545,553 |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. |
Description |
3.1 | Certificate of Amendment to Certificate of Incorporation of Select Medical Holdings Corporation (filed herewith) |
10.1 | Amendment to the 2020 Equity Incentive Plan of Select Medical Holdings Corporation (filed herewith) |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.
SELECT MEDICAL HOLDINGS CORPORATION | ||
Date: April 26, 2024 | By: | /s/ Michael E. Tarvin |
Michael E. Tarvin | ||
Executive Vice President, General Counsel and Secretary |
Exhibit 3.1
Execution Version
CERTIFICATE OF AMENDMENT
OF THE
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
OF
SELECT MEDICAL HOLDINGS CORPORATION.
Select Medical Holdings Corporation, a corporation incorporated and existing under and by the virtue of the General Corporation Law of the State of Delaware (the “Corporation”) does hereby certify:
FIRST: That, at a meeting of the Board of Directors of the Corporation (the “Board of Directors”) on February 13, 2024, a resolution was duly adopted setting forth a proposed amendment to the Amendment and Restated Certificate of Incorporation of the Corporation in the form set forth below (the “Amendment”), declaring said Amendment to be advisable and calling for consideration of said proposed Amendment by the stockholders of the Corporation.
“RESOLVED, that Article TENTH of Amended and Restated Certificate of Incorporation of the Corporation shall be amended and restated in its entirety and shall be and read as follows:
TENTH: Indemnification. The corporation shall indemnify each of the Corporation’s Directors or officers in each and every situation where, under Section 145 of the General Corporation Law of the State of Delaware, as amended from time to time (“Section 145”), the Corporation is permitted or empowered to make such indemnification. The corporation may, in the sole discretion of the Board, indemnify any other person who may be indemnified pursuant to Section 145 to the extent the Board deems advisable, as permitted by Section 145. The corporation shall promptly make or cause to be made any determination required to be made pursuant to Section 145.
No person shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a Director or an officer, provided, however, that the foregoing shall not eliminate or limit the liability (i) of a Director or an officer for any breach of the Director’s or officer’s duty of loyalty to the Corporation or its stockholders, (ii) of a Director or an officer for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) of a Director under Section 174 of the General Corporation Law of the State of Delaware, (iv) of a Director or an officer for any transaction from which the Director or officer derived an improper personal benefit or (v) of an officer in any action by or in the right of the Corporation. If the General Corporation Law of the State of Delaware is subsequently amended to further eliminate or limit the liability of a Director or an officer, then a Director or an officer of the Corporation, in addition to the circumstances in which a Director or an officer is not personally liable as set forth in the preceding sentence, shall not be liable to the fullest extent permitted by the amended General Corporation Law of the State of Delaware. For purposes of this Article TENTH, “fiduciary duty as a Director or an officer” shall include any fiduciary duty arising out of serving at the Corporation’s request as a director or an officer of another corporation, partnership, joint venture or other enterprise, and “personal liability to the Corporation or its stockholders” shall include any liability to such other corporation, partnership, joint venture, trust or other enterprise, and any liability to the Corporation in its capacity as a security holder, joint venturer, partner, beneficiary, creditor or investor of or in any such other corporation, partnership, joint venture, trust or other enterprise.”
SECOND: That, thereafter, pursuant to the resolution of the Board of Directors, the proposed Amendment was approved by the stockholders of the Corporation at the annual meeting of stockholders on April 25, 2024.
THIRD: That the Amendment was duly adopted in accordance with the provisions of Sections 242 of the General Corporation Law of the State of Delaware.
[signature page follows]
IN WITNESS WHEREOF, Select Medical Holdings Corporation has caused this Amendment to the Amended and Restated Certificate of Incorporation to be executed by its duly authorized officer on this 26th day of April, 2024.
SELECT MEDICAL HOLDINGS CORPORATION | ||
By: | /s/ Michael E. Tarvin | |
Name: | Michael E. Tarvin | |
Title: | Senior Executive Vice President, General Counsel and Secretary |
Exhibit 10.1
Execution Version
Amendment No. 1
Select Medical Holdings Corporation
2020 Equity Incentive Plan
April 25, 2024
Pursuant to the power reserved to it in Section 9.1 of the Select Medical Holdings Corporation 2020 Equity Incentive Plan (the “Plan”), the Board of Directors of Select Medical Holdings Corporation hereby amends the Plan, effective February 13, 2024, as follows:
1. Section 5.1 is hereby amended and restated in its entirety to read as follows:
“5.1. Subject to adjustment as provided in Section 8 hereof and this Section 5, not more than 5,925,000 Shares may be delivered, in the aggregate, pursuant to the Plan on or after the Effective Date with respect to Awards (the “Share Reserve”). No more than 5,925,000 Shares issued under the Plan may be issued pursuant to the exercise of Incentive Stock Options. The Shares issued under the Plan may, at the election of the Board, be (i) authorized but previously unissued Shares or (ii) Shares previously issued and outstanding and reacquired by the Company. No individual shall be eligible to receive, in any one calendar year, Awards with respect to more than 2,000,000 Shares (subject to adjustment as provided in Section 8 hereof). Notwithstanding the foregoing, Shares issued under Awards granted in assumption, substitution or exchange for previously granted awards of a company acquired by the Company or any Subsidiary (“Substitute Awards”) shall not reduce the Shares available under the Plan, and to the extent permitted by the rules of the stock exchange on which the Shares are then listed or quoted, shares under a stockholder approved plan of an acquired company (adjusted to reflect the transaction) may be used for Awards under the Plan and do not reduce the Share Reserve. No Non-Employee Director who is a member of the Board may be granted Awards covering more than 50,000 Shares in any one calendar year.”
2. A new Section 6.8 shall be inserted immediately following Section 6.7, as follows:
“6.8. Minimum Vesting Period. Notwithstanding anything to the contrary in the Plan, the minimum vesting schedule applicable to Awards shall provide for vesting over a service period of not less than one (1) year, with vesting only permitted on or following the one (1) year anniversary of the grant date; provided that (i) such limitation shall not apply to Awards granted for up to an aggregate of five percent (5%) of the maximum number of Shares that may be issued under this Plan and (ii) the Committee may, in its sole discretion, accelerate the vesting of Awards subject to such limitation upon a termination of a Participant’s employment or other service with the Company or a Subsidiary without Cause, termination of a Participant’s employment or other service with the Company or a Subsidiary as the result of the Participant’s Disability, a termination of a Participant’s employment or other service with the Company or a Subsidiary as the result of the Participant’s death, or in the event of a Change in Control.”
To record the adoption of this Amendment No. 1 to the Plan, Select Medical Holdings Corporation has authorized its officers to affix its corporate name effective as of the date indicated above.
[Signature Page Follows]
SELECT MEDICAL HOLDINGS CORPORATION | ||
By: | /s/ Michael E. Tarvin | |
Name: | Michael E. Tarvin | |
Title: | Senior Executive Vice President, General Counsel and Secretary |
[Signature Page to Amendment to Equity Incentive Plan]